Ibrutinib treatment also leads to dose‐dependent inhibition of EGFR phosphorylation and it is speculated that it could be a candidate drug for the treatment of EGFR‐mutant, non‐small cell lung cancer 22. The gene discussed is EGFR; the disease is lung cancer.